Xenograft Mouse Models for Tumour Targeting
- 1.8k Downloads
Monoclonal antibodies against tumour-associated antigens have been widely used for targetted therapy of cancer. Most of the pre-clinical assessment of efficacy and toxicity of these agents is carried out in immunodeficient mice xenografted with human tumours. Quantitative biodistribution is routinely assessed by administration of radiolabelled antibodies, followed by counting of radioactivity in tumour and normal tissues. However, in order to optimise the therapy design and synergistic combination of agents, it is desirable to understand the complex antibody-tumour interactions in-vivo and determine which regions of tumours are being targetted. This is achieved by quantitative, high resolution fluorescence microscopy, which can be employed to demonstrate the distribution and therapeutic efficacy of the targetting antibody in relation to the tumour microenvironment.
KeywordsLS174T Cell PD10 Column Welwyn Garden City Green Needle Radiolabelled Antibody
We thank Dr Ethaar El-Emir for skillful technical assistance and Cancer Research UK and European Union FP7 (201342-ADAMANT) for grant support.
- Fidarova EF, El-Emir E, Boxer GM, Qureshi U, Dearling JL, Robson MP, Begent RH, Trott KR, Pedley RB (2008) Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy. Clin Cancer Res 14:2639–2646PubMedCrossRefGoogle Scholar
- Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH (2008) Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 61:4716–4722Google Scholar